tbuckley/cabot-search huggingface dataset:
Abstract 9418: Contrast Volume to Estimated Glomerular Filtration Rate Ratio as a Predictor for 30-Day All-Cause Mortality After Transcatheter Aortic Valve Implantation
Authors: Omar Chehab, Clarissa Ng Yin Ling, Samuel Hale, Samuel Malomo, Juliet C Berner, Nanci O'Reilly, Anthony Mathur, Andreas Baumbach, Mick Ozkor, Simon Kennon, Michael Mullen
Journal: Circulation (2021)

Introduction: Contrast-induced acute kidney injury (AKI) has been proven to be associated with early mortality and adverse events. However, in the setting of transcatheter aortic valve implantation (TAVI), previous literature has failed to establish a correlation between the absolute volume of contrast media administered and mortality. Objective: We aimed to investigate the impact of contrast volume administered normalised to estimated glomerular filtration rate ratio (V/eGFR) on 30-day all-cause mortality in TAVI patients. Secondary outcomes were AKI and new renal replacement therapy (RRT). Methods: We retrospectively analysed a cohort of 1150 patients who underwent TAVI at our unit between 2015-2018. Results: Follow-up was complete for all patients. There were 23 deaths within the follow-up period. Receiver operating curve (ROC) analysis showed fair discrimination for 30-day all-cause mortality at a V/eGFR ratio of 3.6 (C-statistic 0.68). 69.7% (n=801) of patients had a V/eGFR of &lt;3.6 and 30.3% (n=349) had a V/eGFR of ≥3.6. In multivariate Cox proportional hazards analysis, V/eGFR as a cut point ≥3.6 was the strongest predictor of 30-day all-cause mortality (hazards ratio 4.35, 95% confidence interval [1.74-10.89], p=0.002). Other independent predictors were procedural urgency (3.40 [1.46-7.92]) and being under general anaesthesia (4.23 [1.62-11.08]). In Kaplan-Meier analysis, patients with V/eGFR ≥3.6 had a significantly greater 30-day mortality than those &lt;3.6 (log rank test p&lt;0.0001). A similar V/eGFR cut point of 3.6 was found to be an excellent predictor for new RRT (C-statistic 0.82), and 3.3 for AKI (C-statistic 0.60). Conclusions: In conclusion, a V/eGFR ≥3.6 after TAVI was found to be a strong predictor of 30-day mortality. The maximum contrast volume which can be safely administered in each patient without significantly increasing the risk of mortality can be calculated using this ratio. Future studies are indicated to validate our findings.
H3K36 Trimethylation Mediated By SETD2 Regulates Cell Proliferation and Cell Cycle By Modulating BCMA-JNK and c-Myc Pathways in Multiple Myeloma
Authors: Pan Zhou, Mengyu Xiao, Yanliang Bai, Huixia Cao, Weiping Yuan, Fengmin Shao, Kai Sun
Journal: Blood (2021)
Abstract 12986: Association of Gestational Diabetes With Subclinical Cardiovascular Disease on Echocardiogram and Endothelial Function Testing
Authors: Anum Minhas, Malamo E Countouris, Chiadi E Ndumele, Elizabeth Selvin, Arthur J Vaught, Robin Gandley, Allison Hays, Pamela Ouyang, Wendy L Bennett, Janet M Catov, Erin Michos
Journal: Circulation (2021)

Introduction: Gestational diabetes mellitus (GDM) increases risk for cardiovascular disease (CVD). The subclinical cardiovascular structural and functional changes that contribute to long-term cardiovascular risk are unclear. Hypothesis: We hypothesized that GDM is associated with adverse cardiovascular remodeling, diastolic function abnormalities, and endothelial dysfunction at approximately a decade after delivery, thereby increasing CVD risk. Methods: We conducted a cross-sectional analysis of women from an existing cohort with abstracted clinical pregnancy data. Women attended a follow-up visit at a median of 9 years after delivery. Echocardiograms, Peripheral Arterial Tonometry (EndoPAT), glycocalyx analysis (GlycoCheck) and laboratory testing were conducted at the follow-up visit. Results: Among 217 women who attended the follow-up visit, 53 (24%) had history of GDM. After adjusting for age, race, preeclampsia history or preterm delivery, women with prior Compared to women without GDM, women with prior GDM had higher interventricular septal and left ventricular (LV) posterior wall thickness and lower septal e’ velocity ( Table ; Model 2). They also had worse endothelial function with lower reactive hyperemia index (RHI) and adverse GlycoCheck parameters. Measures of hypertrophy were attenuated by additional adjustment for body mass index, hypertension, and diabetes (Model 3), but findings of adverse LV diastology, RHI and GlycoCheck parameters remained significant. Conclusions: Women with GDM were more likely to have increased LV wall thickness, adverse diastology and endothelial dysfunction nearly a decade postpartum. Adjusting for traditional cardiovascular risk factors attenuated some but not all parameters. These findings suggest that subclinical structural and functional cardiac and vascular changes may be a mechanism by which GDM causes increased risk of CVD.
Abstract 9338: In-hospital Complications During 35747 Permanent Pacemaker Implantations from 2009-2018: A Statewide Australian Cohort Study
Authors: Vijayatubini Vijayarajan, Austin Chin Chwan Ng, David Brieger, Vincent Chow, Leonard Kritharides
Journal: Circulation (2021)

Background: Permanent pacemaker implantation (PPI) is standard of care for significant bradyarrhythmia since the early 1960’s. Understanding its utilisation and projection in our ageing populations has important implications on medical resource utilisation. This study reports the rates of PPI in the state of New South Wales (NSW), Australia from 2009-2018. Hypothesis: We hypothesized PPI in patients ≥80yrs has increased faster than in &lt;80yrs over past decade. Methods: We examined the prevalence of PPI from Jan 2009 to Dec 2018 by extracting administrative details of all permanent pacemakers implanted statewide, including patient’s characteristics and in-hospital complications using the NSW Centre-for-Health-Record-Linkage datasets. All analysis was stratified by age &lt;80yrs vs ≥80yrs old. Results: A total of 35747 admissions involved PPI (60% males) during the study period. The mean ±SD implantation rate and age was 3574±311 PPI per annum and 78±10yrs respectively. 18187 (50.9%) of PPI were in patients ≥80yrs. The mean annual rate of PPI was 593.4±57.6 per 100000 persons for ≥80yrs, compared to 24.5±2.1 per 100000 persons in &lt;80yrs (p=0.0001). The overall mean rate of increase in PPI from 2009-2018 for ≥80yrs old was 2.6±3.7% compared to 1.7±3.2% per annum in &lt;80yrs (p=0.001). The median (interquartile range [IQR]) length of stay (LOS) in patients ≥80yrs requiring emergency PPI was 8 (5-14) days, compared to 1 (1-3) days in those who had an elective PPI procedure, p&lt;0.05. For patients &lt;80yrs old, the median (IQR) LOS was 7 (4-12) days compared to 1 (1- 2) days, p&lt;0.05 respectively. Overall, complications of pacemaker implantation excluding death was 8%. Although overall in-hospital mortality was low, it was higher for patients ≥80yrs compared to the &lt;80yrs group (0.9% vs 0.6%; p&lt;0.001). Overall complication rates declined only in last two years of the study period, with no significant change for in hospital death. Conclusion: Overall PPI increased between 2009-2018, with the increase greatest in patients ≥80yrs. Overall complication rates remained elevated, with in-hospital mortality higher in the older group. Future studies should examine strategies that reduce in-hospital complications during pacemaker implantations.
Naturalizing laboratory mice by housing in a farmyard-type habitat confers protection against colorectal carcinogenesis
Authors: Henriette Arnesen, Thomas C. A. Hitch, Christina Steppeler, Mette Helen Bjørge Müller, Linn Emilie Knutsen, Gjermund Gunnes, Inga Leena Angell, Ida Ormaasen, Knut Rudi, Jan Erik Paulsen, Thomas Clavel, Harald Carlsen, Preben Boysen
Journal: Gut Microbes (2021)

Living in a farm environment in proximity to animals is associated with reduced risk of developing allergies and asthma, and has been suggested to protect against other diseases, such as inflammatory bowel disease and cancer. Despite epidemiological evidence, experimental disease models that recapitulate such environments are needed to understand the underlying mechanisms. In this study, we show that feralizing conventional inbred mice by continuous exposure to a livestock farmyard-type environment conferred protection toward colorectal carcinogenesis. Two independent experimental approaches for colorectal cancer induction were used; spontaneous (Apc Min/+ mice on an A/J background) or chemical (AOM/DSS). In contrast to conventionally reared laboratory mice, the feralized mouse gut microbiota structure remained stable and resistant to mutagen- and colitis-induced neoplasia. Moreover, the feralized mice exhibited signs of a more mature immunophenotype, indicated by increased expression of NK and T-cell maturation markers, and a more potent IFN-γ response to stimuli. In our study, hygienically born and raised mice subsequently feralized post-weaning were protected to a similar level as life-long exposed mice, although the greatest effect was seen upon neonatal exposure. Collectively, we show protective implications of a farmyard-type environment on colorectal cancer development and demonstrate the utility of a novel animal modeling approach that recapitulates realistic disease responses in a naturalized mammal.
A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction—Reply
Authors: Adam D. DeVore, Bradi Granger, Adrian F. Hernandez
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu
Authors: Yao Yao, Tommaso Perini, Mehmet K. Samur, Raphael Szalat, Moritz Binder, Kenneth C. Anderson, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2021)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Authors: Naval Daver, Marina Konopleva, Abhishek Maiti, Tapan M. Kadia, Courtney D. DiNardo, Sanam Loghavi, Naveen Pemmaraju, Elias J. Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Michelle Golez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Hussein A Abbas, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood (2021)
David Oliver: The cultural problems still affecting PPE provision
Authors: David Oliver
Journal: BMJ (2021)

In February I wrote a news story in The BMJ about failings in the supply of personal protective equipment (PPE) for frontline NHS hospital staff. It was based on freedom of information (FOI) requests sent to 130 trusts, triangulated against the Doctors’ Association UK’s database of reports from its members.1 I went to press with 66 responses, but I’ve now received a further 21. I asked each trust the same four questions:

In my report I found the default mode to be denial, and the same is true of the more recent responses. My initial story …
<i>IFN-γ Inhibitors and Ruxolitinib Therapy for Acquired Severe Aplastic Anemia in an Ex-Vivo Model</i>
Authors: Edo Schaefer, Yanling Liao, Bernadette Fallon, Janet Ayello, Melanie Peters, Jian Pan, Morgan Anderson-Crannage, Mitchell S Cairo
Journal: Blood (2021)
Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
Authors: Elisabeth Mahase
Journal: BMJ (2021)

<h3>Background and Objectives</h3> Preventing complications of stroke such as poststroke aspiration pneumonia (PSAP) may improve stroke outcomes in resource-limited settings. We investigated the incidence and associated mortality of PSAP in Zambia. <h3>Methods</h3> We conducted a prospective cohort study of adults with stroke at University Teaching Hospital (Lusaka, Zambia) between December 2019 and March 2020. NIH Stroke Scale, Glasgow Coma Scale, and Modified Rankin Scale scores and 9 indicators of possible PSAP were collected serially over each participant9s admission. PSAP was defined as ≥4 indicators present, and possible PSAP as 2%–3% present. T tests and χ<sup>2</sup> tests were used to compare clinical parameters across PSAP groups. Logistic regression was used to assess the relative effects of age, sex, PSAP status, and initial stroke severity on inpatient mortality. <h3>Results</h3> We enrolled 125 participants. Mean age was 60 ± 16 years, 61% were female, 55% of strokes were ischemic, and the baseline NIH Stroke Scale score was 19.7 ± 8.7. Thirty-eight (30%) had PSAP, and 32 (26%) had possible PSAP. PSAP was associated with older age and more adverse stroke severity scores. Fifty-nine percent of participants with PSAP died compared with 39% with possible PSAP and 8% with no PSAP. PSAP status independently predicted inpatient mortality after controlling for age, sex, and initial stroke severity. Swallow screening was not performed for any participant. <h3>Discussion</h3> PSAP is common and life threatening in Zambia, especially among older participants with severe stroke presentations. PSAP was associated with significantly increased mortality independent of initial stroke severity, suggesting that interventions to mitigate PSAP may improve stroke outcomes in Zambia and other resource-limited settings.
Re-print: Ranolazine may be the Best and Safest Pharmacologic Therapy for Congestive Heart Failure, and Safe, Effective for Ventricular and Atrial Arrhythmias
Authors: Gary L Murray
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

Background: Ranolazine (RAN) reduces cardiac sodium channel 1.5’s late sodium current(INaL ) in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular ejection fraction(LVEF) and reducing arrhyth- mogenic after potentials. RAN blocks neuronal sodium channel 1.7(Nav 1.7), potentially altering parasympathetic and sympathetic (P&amp;S) activity. RAN also selectively blocks inactivated atrial Nav 1.8, as well as ventricular IKr and ICaL, affecting atrial and ventric- ular arrhythmias. Methods: (1)Matched CHF patients were given RAN (1000 mg p.o. b.i.d.) added to guideline-driven therapy (RANCHF, 41 systolic, 13 diastolic) or no adjuvant therapy (control, NORANCHF, 43 systolic, 12 diastolic). Echocardiographic LVEF and P&amp;S measures were obtained at baseline and follow-up (mean 23.7 months). (2)A total of 59 patients with symptomatic PVCs were identified from full-disclosure Holters. Doses of 500 - 1,000 mg RAN b.i.d. were given to 34% and 66% of patients, respectively, and Holters were repeated (mean 3.1 months). Congestive heart failure (CHF) was defined as symptoms including dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and edema, with a brain natriuretic peptide &gt; 400. Systolic heart failure with reduced ejection fraction (HFr EF) vs. diastolic CHF (HFpEF) depended upon LVEF≥ 40%. Results: (1)LVEF increased in 70% of RANCHF patients, an average of 11.3 units. Mean LVEF remained unchanged in NORANCHF pa- tients. P&amp;S measures indicated cardiovascular autonomic neuropathy (P&lt;0.10 bpm2) in 20% of NORANCHF patients at baseline and 29% at follow-up (increasing in both groups). At baseline, 28% of patients had high sympathovagal balance (SB), RAN normalized SB in over 50% of these; in contrast, the NORANCHF group had a 20% increase in patients with high SB. (2)Upon repeat Holters at a mean of 3.1 months after initiating RAN, 95% (56/59) of the patients had their PVC count reduced: 24% (14/59) had more than 90% decrease, 34% (20/59) had 71 to 90% decrease, and 17% (10/59) had 50 to 70% decrease. In the entire group, RAN reduced PVCs by 71% (mean 13,329 to 3,837; p &lt; 0.001). Ventricular bigeminy was reduced by 80% (4,168 to 851; p &lt; 0.001), ventricular couplets were reduced by 78% (374 to 81; p &lt; 0.001), and ventricular tachycardia (VT) was reduced by 91% (56 to 5; p &lt; 0.001). The PVC reduction was dose dependent without proarrhythmia. Conclusions: (1)RAN preserves or improves LVEF and decreases high SB in CHF. (2)RAN offers an effective and safe pharmacologic treatment for symptomatic PVCs.
Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)
Authors: Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, Jim A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S Kean, K. Scott Baker, Lauri S Burroughs, Jeffrey R. Andolina, Michael B Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh
Journal: Blood (2021)
Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody
Authors: Fabrizio De Benedetti, Alexei A Grom, Paul Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Pierre Quartier, Jordi Antón, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Cristina de Min
Journal: Blood (2021)
Automated Comprehensive Diagnostics of Hematologic Neoplasms By Artificial Intelligence Models Using Flow Cytometric Raw Matrix Data
Authors: Frauke Bellos, Kim Pawelka, Elena Fortina, Manusnan Suriyalaksh, Sven Maschek, Claudia Haferlach, Manja Meggendorfer, Torsten Haferlach, Wolfgang Kern
Journal: Blood (2021)
Abstract 9844: Virtual Outreach Facilitates Blood Pressure Self-Monitoring Among Black Men at a Federally Qualified Health Center
Authors: Evan M Murray, Ashwin Gadiraju, Rohan Gupta, Anthony Tarakji, Sandra Au, Daniel tounsel, Unique Whitehurst, Bradi B Granger, Holly Biola
Journal: Circulation (2021)

Introduction: Rates of uncontrolled hypertension are higher in Black men than in the general population. Prior studies have shown that home self-monitoring of blood pressure (SMBP), in addition to clinical support and education, helps patients lower their blood pressure (BP). This study evaluated a SMBP program for Black men with hypertension at a Federally Qualified Health Center (FQHC). Hypothesis: We hypothesized that virtual outreach would increase SMBP adoption and lower BP among Black Men at a FQHC. Methods: Black men &gt;18 years old with severe hypertension (&gt;160 mmHg systolic or &gt; 100 mmHg diastolic) were contacted by student volunteers and offered a free BP cuff with program enrollment. Students attempted &gt; 4 calls with each participant over the course of 2 plan-do-study-act (PDSA) cycles. Students provided BP education and asked participants to report SMBP readings. Univariate analyses were performed to explore the effect of our SMBP program on clinic BPs. Results: Of 258 eligible, 137 (53.1%) were successfully contacted and 82 (31.8%) received a BP cuff. By the end of PDSA cycle 2, 52 men (20.2%) had reported a BP reading to their student caller. For those who had an updated BP documented in the medical record after cycle 1, subsequent office systolic BP changed by an average of -24.9 (95% CI: -30.8, -19.0) mmHg for the 37 men who used their BP cuff (p&lt;0.001) and by -21.4 (95% CI: -25.1, -16.8) mmHg for the 108 men who did not (p&lt;0.001). The reduction in BP was larger for the group that used BP cuffs (difference -3.5 [95% CI: -12.1, 5.1] mmHg, p=0.35), but this change was not statistically significant. Conclusions: Creating partnerships via virtual communication between university students and community members led to adoption of SMBP among Black men. BP reduction trended greater in the group that began self-monitoring, but difficulty in follow-up and a small sample size limited statistical power.
High Toxicity and Poor Survival with Association CHOP Plus Etoposide Compared to CHOP Regimen in 124 Brazilian Patients with Nodal PTCL Lymphomas (nPTCL): A Real-Life Experience
Authors: Luis Alberto de Padua Covas Lage, Claudio Vinicius Brito, Guilherme Carneiro Barreto, Cadiele Oliana Reichert, Débora Levy, Hebert Fabricio Culler, Maria Cláudia Nogueira Zerbini, Vanderson Rocha, Juliana Pereira
Journal: Blood (2021)
Abstract 9043: Prognostic Significance and Interplay Between Heart Failure and Covid-19
Authors: Stephen J Greene, Dominik Lautsch, Lingfeng Yang, Xi Tan, JoAnne Brady
Journal: Circulation (2021)

Introduction: COVID-19 may negatively impact prognosis for patients with chronic HFrEF, and vice versa. However, large-scale data characterizing the interplay of COVID-19 and HFrEF on clinical outcomes are scarce. Methods: We examined the TriNetX health database from January 2020-September 2020 to conduct 2 analyses. Analysis A excluded patients with HFpEF and included patients with a positive inpatient or outpatient test for COVID-19, with a 3-way comparison of patients 1) without prior HF, 2) HFrEF without recent worsening HF event (WHFE) (i.e., no HF hospitalization or outpatient IV diuretic within prior 1 year), and 3) worsening HFrEF (i.e., HF hospitalization or outpatient IV diuretic within prior 1 year). Outcomes included mortality at 30 days and composite all-cause mortality or hospitalization following COVID-19 test. Analysis B included patients with HFrEF who underwent PCR testing for COVID-19, and compared patients with a positive versus negative test. Outcomes were mortality at 30 days and worsening HF (i.e., HF hospitalization or outpatient IV diuretic use). Results: In analysis A, 98,014 (99%) patients had no prior HF, 524 (0.5%) had HFrEF without WHFE, and 514 (0.5%) had worsening HFrEF. After adjustment for confounders, compared with patients without HF, worsening HFrEF was independently associated with excess mortality (p&lt;0.01), whereas HFrEF without WHFE was not statistically significant (p=0.06) (Table) . In analysis B, 1,038 (7%) had a positive test for COVID-19 and 13,800 (93%) had only negative tests. After adjustment, testing positive for COVID-19 was independently associated with mortality and worsening HF (all p&lt;0.01). Conclusions: In this US population of ambulatory and hospitalized patients, after accounting for confounders, worsening HFrEF was independently associated with excess mortality after COVID-19 infection. Among patients with HFrEF, COVID-19 infection was associated with higher risk of death and worsening HF events.
Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study
Authors: Elisa Molinelli, Claudia Sapigni, Oriana Simonetti, Valerio Brisigotti, Katia Giuliodori, Annamaria Offidani
Journal: Journal of the American Academy of Dermatology (2021)